Atreca, Inc.
atreca.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 14, 2023. Its latest SEC filing is a DEFM14A from Apr 22, 2024.
10-Q for Q3 FY2023, filed Nov 14, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops antibody-based treatment candidates for solid tumors and malaria using a platform that draws on human immune responses.
10-K for FY2022, filed Mar 29, 2023
How Did They Make Money?
No revenue was reported.
10-K for FY2022, filed Mar 29, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 14, 2023
−$36.2MView ↗
- ▲ +57% (Loss)
- vs −$23.1M in Q3 FY2022
-
Mar 11, 2024
Nasdaq notified Atreca its shares would be delisted
Nasdaq said the shares would be suspended and delisted after Atreca failed to regain the minimum bid-price requirement.
Sources
8-K, filed Mar 11, 2024
On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the…View ↗
-
Dec 26, 2023
Agreed to sell antibody assets to Immunome
Immunome agreed to buy preclinical oncology antibody assets that Atreca said constitute substantially all its assets; the sale required stockholder approval.
Sources
8-K, filed Dec 26, 2023
On December 22, 2023, (the “Execution Date”) Atreca, Inc., a Delaware corporation (the “Company”), and Immunome, Inc. (“Purchaser”)…View ↗
-
Sep 21, 2023
Chief financial officer resigned
Chief executive John Orwin was appointed principal financial officer.
Sources
8-K, filed Sep 21, 2023
Departure of Chief Financial OfficerView ↗
-
Aug 10, 2023
Suspended ATRC-101 and reorganized operations
The reorganization included workforce cuts and a shift toward preclinical antibody-drug conjugate candidates, including APN-497444.
Sources
8-K, filed Aug 10, 2023
In addition, the Company announced plans to focus its efforts on advancing its preclinical antibody-drug conjugate candidates, including…View ↗
Malaria prevention added
The latest report extends the pipeline beyond cancer with a malaria-prevention antibody licensed to Gates MRI, while the older report describes oncology candidates.
10-K for FY2019, filed Mar 11, 2020 10-K for FY2022, filed Mar 29, 2023Beyond oncology, in October 2021, we entered into a licensing agreement with the Bill & Melinda Gates Medical Research Institute or Gates…View ↗
More antibody formats
The oncology pipeline broadens from the older report’s description of bispecific antibodies to also include antibody-drug conjugates and T-cell-engaging bispecifics.
10-K for FY2019, filed Mar 11, 2020 10-K for FY2022, filed Mar 29, 2023Continue efforts to develop a pipeline of antibody-based product candidates for oncology. While our only product candidate that is…View ↗
Partnering expands
Partnering shifts from the older report’s description of accessing collaborators’ technologies and expertise to also include discovery work for pharma and biotech partners intended to bring in payments.
10-K for FY2019, filed Mar 11, 2020 10-K for FY2022, filed Mar 29, 2023Selectively enter into collaborations to enhance and expand our product pipeline as well as our drug development capabilities. We believe…View ↗
Who Did They Compete With?
Competes with Adaptive Biotechnologies, Neurimmune, OncoResponse, Immunome, Vir Biotechnology, AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck &
10-K for FY2022, filed Mar 29, 2023We expect to compete with antibody, biologics and other therapeutic platforms and development companies who are also pursuing a similar…View ↗
Loading...
